Cited by 151Neuroscience and Neuropharmacology ResearchSchizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Glutamate Receptor Subtypes Mediating Synaptic Activation of Prefrontal Cortex Neurons: Relevance for Schizophrenia

Open access
Rotaru, Diana C., Yoshino, Hiroki, Lewis, David A., Ermentrout, G. Bard, Gonzalez-Burgos, Guillermo·2011·The Journal of Neuroscience

Abstract

Schizophrenia may involve hypofunction of NMDA receptor (NMDAR)-mediated signaling, and alterations in parvalbumin-positive fast-spiking (FS) GABA neurons that may cause abnormal gamma oscillations. It was recently hypothesized that prefrontal cortex (PFC) FS neuron activity is highly dependent on NMDAR activation and that, consequently, FS neuron dysfunction in schizophrenia is secondary to NMDAR hypofunction. However, NMDARs are abundant in synapses onto PFC pyramidal neurons; thus, a key question is whether FS neuron or pyramidal cell activation is more dependent on NMDARs. We examined the AMPAR and NMDAR contribution to synaptic activation of FS neurons and pyramidal cells in the PFC of adult mice. In FS neurons, EPSCs had fast decay and weak NMDAR contribution, whereas in pyramidal cells, EPSCs were significantly prolonged by NMDAR-mediated currents. Moreover, the AMPAR/NMDAR EPSC ratio was higher in FS cells. NMDAR antagonists decreased EPSPs and EPSP–spike coupling more strongly in pyramidal cells than in FS neurons, showing that FS neuron activation is less NMDAR dependent than pyramidal cell excitation. The precise EPSP–spike coupling produced by fast-decaying EPSCs in FS cells may be important for network mechanisms of gamma oscillations based on feedback inhibition. To test this possibility, we used simulations in a computational network of reciprocally connected FS neurons and pyramidal cells and found that brief AMPAR-mediated FS neuron activation is crucial to synchronize, via feedback inhibition, pyramidal cells in the gamma frequency band. Our results raise interesting questions about the mechanisms that might link NMDAR hypofunction to alterations of FS neurons in schizophrenia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1970-10.2011

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rotaru, D. C., Yoshino, H., Lewis, D. A., Ermentrout, G. B., & Gonzalez-Burgos, G.
Affiliations
University of Pittsburgh (US)
Venue
The Journal of Neuroscience
Published
2011-01-05
Volume
31
Issue
1
Pages
142-156
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W1988282606
Cited by
151
References
127
Citations by year
2026: 5 · 2025: 8 · 2024: 4 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 7 · 2019: 6 · 2018: 11 · 2017: 11 · 2016: 10 · 2015: 15 · 2014: 14 · 2013: 15 · 2012: 14
FWCI
7.55
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • SK Life Science
  • National Institutes of Health (MH084053)
  • National Institute of Mental Health (P50MH084053, MH084053, R01MH043784)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
schizophrenia, NMDA receptor hypofunction, prefrontal cortex, pyramidal neurons, AMPA receptors, glutamate receptor subtypes, synaptic excitation, gamma oscillations, product inhibition
MeSH terms
Action Potentials, Animals, Biophysics, Computer Simulation, Electric Stimulation, Female, Lysine, Male, Membrane Potentials, Mice, Inbred C57BL, Models, Neurological, Neurons, Probability, Pyridazines, Synapses, Prefrontal Cortex, Receptors, Glutamate, Patch-Clamp Techniques, Excitatory Amino Acid Antagonists, Statistics, Nonparametric, GABA Antagonists, Excitatory Postsynaptic Potentials, Mice, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review